Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Current Deferred Revenue for 9 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a N/A change, with the full-year FY2025 number at $2.7 million, changed N/A from a year prior.
  • Current Deferred Revenue was $2.7 million for Q4 2025 at Akebia Therapeutics, down from $3.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $48.3 million in Q2 2022 to a low of $319000.0 in Q1 2022.
  • A 5-year average of $27.7 million and a median of $43.3 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 13472.41% in 2023, then plummeted 97.18% in 2025.
  • Akebia Therapeutics' Current Deferred Revenue stood at $3.2 million in 2021, then skyrocketed by 1383.25% to $47.0 million in 2022, then fell by 7.95% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then tumbled by 93.81% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Current Deferred Revenue are $2.7 million (Q4 2025), $3.9 million (Q3 2025), and $5.5 million (Q2 2025).